Latest:
Dr. Chu Discusses CNS Penetration of Ceritinib
Quincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
R. Kate Kelley
Latest:
Dr. Kelley on Newly Approved Agents in HCC
R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).
R. Lor Randall, MD, FACS
R. Lor Randall, MD, FACS, is the David Linn Endowed Chair for Orthopedic Surgery and chair of the Department of Orthopedic Surgery as well as a professor at the University of California Davis.
Latest:
Dr Randall on the Multidisciplinary Foundation of Research Into Sarcoma Survivorship
R. Lor Randall, MD, FACS, discusses the multidisciplinary nature of research aiming to develop a predictive model of sarcoma survivorship.
Raajit K. Rampal, MD, PhD
Raajit Rampal, MD, is director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Latest:
Dr Rampal on the Benefits and Limitations of JAK Inhibitors in Myelofibrosis
Raajit Rampal, MD, discusses treatment decision-making factors, such as JAK inhibitor efficacy and signs of treatment failure, for myelofibrosis.
Rachel A. Freedman, MD, MPH
Latest:
Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer
Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
Rachel N. Grisham, MD
Rachel N. Grisham, MD, is an associate attending physician at Memorial Sloan Kettering Cancer Center in New York, New York
Latest:
Dr Grisham on the FDA Approval of Avutometinib/Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer
Rachel Grisham, MD, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated, recurrent low-grade serous ovarian cancer.
Rachel Narozniak, MA
Latest:
Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL
Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.